TITLE:
Treatment with Enterococcus faecalis CECT7121 Is Not Effective as Therapy in Mice with an Established Allergy Status
AUTHORS:
Ailén M. Díaz, Matías A. Molina, Guillermo G. Nuñez, Ana C. Mourelle, Mónica D. Sparo, Marcela A. Manghi, Marisa S. Castro
KEYWORDS:
Enterococcus faecalis CECT7121, Ovalbumin-Allergy Murine Model, Immunoglobulin E, Th2 Cytokines, Probiotics
JOURNAL NAME:
Advances in Microbiology,
Vol.7 No.10,
October
31,
2017
ABSTRACT: In allergies, an unbalanced immune response towards a T helper (Th) 2 profile
with high levels of Immunoglobulin (Ig) E is produced. We have demonstrated
that the pre-administration of Enterococcus faecalis CECT7121 prevents
the development of allergy in ovalbumin-immunized mice. In this work,
we evaluated whether this bacterium can also revert an established allergic
status. Mice were immunized with ovalbumin (OVA) and after that, were inoculated
with an E. faecalis CECT7121 suspension. In immunized animals,
serum specific immune response, proliferative activity of memory splenocytes,
and levels of Th2 cytokines were assessed. The in vivo active cutaneous anaphylaxis
test was also performed. The treatment with E. faecalis CECT7121
only increased anti-OVA IgG2a levels. No differences were observed in other
specific immunological parameters. Probiotic-treatment did not prove to have
any desensitizing effect on mice. These results, together with those recently
published, can be concluded that this bacterium would not be appropriate for
the treatment of allergic symptoms.